Trial Outcomes & Findings for Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma (NCT NCT01806064)

NCT ID: NCT01806064

Last Updated: 2020-10-19

Results Overview

Phase 1b: For dose limiting toxicity (DLT) evaluation, severity (grade) was classified according to common terminology criteria for adverse events version 4.0 (CTCAE v4.0).

• Recruitment status: TERMINATED
• Study phase: PHASE1/PHASE2
• Target enrollment: 173 participants
• Primary outcome timeframe: 12 Months
• Results posted on: 2020-10-19

Participant Flow

23 patients enrolled in phase 1b portion. 150 patients randomized in the phase 2 portion.

Participant milestones

Measure	P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID Phase 1b Dose Level 1: 8 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily	P2 Arm A: 5 mg Axitinib BID Phase 2 Arm A: 5 mg Axitinib twice daily	P2 Arm B: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID Phase 2 Arm B: 10 mg/kg TRC105 weekly + 5 mg Axitinib twice daily
Overall Study STARTED	3	15	5	75	75
Overall Study COMPLETED	3	15	5	74	73
Overall Study NOT COMPLETED	0	0	0	1	2

Reasons for withdrawal

Measure	P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID Phase 1b Dose Level 1: 8 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily	P2 Arm A: 5 mg Axitinib BID Phase 2 Arm A: 5 mg Axitinib twice daily	P2 Arm B: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID Phase 2 Arm B: 10 mg/kg TRC105 weekly + 5 mg Axitinib twice daily
Overall Study Randomized Not Enrolled	0	0	0	1	2

Baseline Characteristics

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

Baseline characteristics by cohort

Measure	P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=3 Participants Phase 1b Dose Level 1: 8 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=15 Participants Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID n=5 Participants Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily	P2 Arm A: 5 mg Axitinib BID n=75 Participants Phase 2 Arm A: 5 mg Axitinib twice daily	P2 Arm B: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=75 Participants Phase 2 Arm B: 10 mg/kg TRC105 weekly + 5 mg Axitinib twice daily	Total n=173 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants
Age, Categorical Between 18 and 65 years	0 Participants n=5 Participants	13 Participants n=7 Participants	2 Participants n=5 Participants	35 Participants n=4 Participants	43 Participants n=21 Participants	93 Participants n=8 Participants
Age, Categorical >=65 years	3 Participants n=5 Participants	2 Participants n=7 Participants	3 Participants n=5 Participants	40 Participants n=4 Participants	32 Participants n=21 Participants	80 Participants n=8 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	2 Participants n=7 Participants	2 Participants n=5 Participants	18 Participants n=4 Participants	26 Participants n=21 Participants	48 Participants n=8 Participants
Sex: Female, Male Male	3 Participants n=5 Participants	13 Participants n=7 Participants	3 Participants n=5 Participants	57 Participants n=4 Participants	49 Participants n=21 Participants	125 Participants n=8 Participants
Race/Ethnicity, Customized Caucasian	3 Participants n=5 Participants	12 Participants n=7 Participants	5 Participants n=5 Participants	70 Participants n=4 Participants	71 Participants n=21 Participants	161 Participants n=8 Participants
Race/Ethnicity, Customized Hispanic or Latino	0 Participants n=5 Participants	3 Participants n=7 Participants	0 Participants n=5 Participants	5 Participants n=4 Participants	1 Participants n=21 Participants	9 Participants n=8 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=8 Participants
Race/Ethnicity, Customized Native Hawaiian or other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants
Region of Enrollment Hungary	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	11 participants n=4 Participants	10 participants n=21 Participants	21 participants n=8 Participants
Region of Enrollment United States	3 participants n=5 Participants	15 participants n=7 Participants	5 participants n=5 Participants	56 participants n=4 Participants	59 participants n=21 Participants	138 participants n=8 Participants
Region of Enrollment Czechia	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	8 participants n=4 Participants	5 participants n=21 Participants	13 participants n=8 Participants
Region of Enrollment United Kingdom	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	1 participants n=21 Participants	1 participants n=8 Participants

PRIMARY outcome

Timeframe: 12 Months

Population: Patients who discontinued the study prior to completing the DLT evaluation period were not evaluable.

Phase 1b: For dose limiting toxicity (DLT) evaluation, severity (grade) was classified according to common terminology criteria for adverse events version 4.0 (CTCAE v4.0).

Outcome measures

Measure	P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=3 Participants Phase 1b Dose Level 1: 8 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=15 Participants Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID n=5 Participants Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily
Phase 1b: Number of Patients With DLT	0 Participants	0 Participants	0 Participants	—	—

PRIMARY outcome

Timeframe: 15 Months

Population: 95% confidence interval was applied. "NA" is listed for the confidence interval if there were not enough events to estimate a standard error. For Phase 2 all randomized patients were included in the efficacy population.

Median progression free survival (PFS) of patients with advanced or metastatic RCC by RECIST 1.1. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Outcome measures

Measure	P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=75 Participants Phase 1b Dose Level 1: 8 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=75 Participants Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily
Phase 2: Progression Free Survival (PFS) of Patients With RCC	11.4 Months Interval 5.8 to Confidence interval was not estimable if there were not enough events to estimate a standard error.	6.7 Months Interval 5.6 to 13.1	—	—	—

SECONDARY outcome

Timeframe: 15 Months

Population: For Phase 1b patients with screening and at least one on study scan were included in the efficacy population. For Phase 2 all randomized patients were included in the efficacy population. Patients without a baseline scan and at least 1 on study scan were excluded from analysis.

Number of patients with partial response (PR) or complete response (CR) by RECIST 1.1 criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Outcome measures

Measure	P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=3 Participants Phase 1b Dose Level 1: 8 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=75 Participants Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID n=75 Participants Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=14 Participants Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID n=5 Participants Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily
Phase 1b & 2: Response Rate of Patients With RCC	0 Participants	22 Participants	23 Participants	5 Participants	0 Participants

SECONDARY outcome

Timeframe: 15 Months

Population: For Phase 2 all randomized patients were included in the efficacy population. Patients without a baseline scan and at least 1 on study scan were excluded from analysis.

Overall response (OR) rate is the number of patients with partial response (PR) or complete response (CR) by Choi Criteria. Per Choi criteria for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), A decrease in size ≥ 10% or a decrease in tumor attenuation (Houndsfield units) ≥ 15% on CT and no new lesions; Overall Response (OR) = CR + PR.

Outcome measures

Measure	P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=75 Participants Phase 1b Dose Level 1: 8 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=75 Participants Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily
Phase 2: Overall Response Rate of Patients With RCC by Choi	50 Participants	50 Participants	—	—	—

SECONDARY outcome

Timeframe: 2.5 months (cycle 2 day 15)

Population: In 1b patients with a predose sample collected at cycle 2 day 15 were averaged. Patients who missed a dose of TRC105 prior to cycle 2 day 15 were excluded from the analysis. Additional Phase 1b PK analysis beyond steady state concentration at cycle 2 day 15 were not performed. Samples collected in the phase 2 portion of the study were not analyzed.

Trough Serum TRC105 concentrations at steady state (cycle 2 day 15) were measured using validated ELISA methods.

Outcome measures

Measure	P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=3 Participants Phase 1b Dose Level 1: 8 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=13 Participants Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID n=5 Participants Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily
Phase 1b & 2: Trough Concentrations of TRC105 by Dose Level in Phase 1b	27650 ng/mL Standard Deviation 39103	140022 ng/mL Standard Deviation 45403.01	54375 ng/mL Standard Deviation 23546.5	—	—

SECONDARY outcome

Timeframe: 12 months

Population: Patients must have had a baseline and on study assessment of immunogenicity and their baseline must have been negative. Samples collected in the phase 2 portion of the study were not analyzed.

Anti-product antibody concentration were measured using validated ELISA methods.

Outcome measures

Measure	P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=3 Participants Phase 1b Dose Level 1: 8 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=5 Participants Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID n=5 Participants Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily
Phase 1b & 2: Number of Patients With Development of Immunogenicity Antibodies.	1 Participants	0 Participants	0 Participants	—	—

Adverse Events

P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID

Serious events: 1 serious events

Other events: 3 other events

Deaths: 0 deaths

P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID

Serious events: 4 serious events

Other events: 15 other events

Deaths: 1 deaths

P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID

Serious events: 3 serious events

Other events: 5 other events

Deaths: 0 deaths

P2 Arm A: 5 mg Axitinib BID

Serious events: 27 serious events

Other events: 71 other events

Deaths: 3 deaths

P2 Arm B: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID

Serious events: 28 serious events

Other events: 72 other events

Deaths: 6 deaths

Serious adverse events

Measure	P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=3 participants at risk Phase 1b Dose Level 1: 8 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=15 participants at risk Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID n=5 participants at risk Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily	P2 Arm A: 5 mg Axitinib BID n=74 participants at risk Phase 2 Arm A: 5 mg Axitinib twice daily	P2 Arm B: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=73 participants at risk Phase 2 Arm B: 10 mg/kg TRC105 weekly + 5 mg Axitinib twice daily
Gastrointestinal disorders Abdominal Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • Number of events 3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Acute Heart Failure	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Acute Kidney Injury	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • Number of events 3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Blood and lymphatic system disorders Anaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • Number of events 8 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Hepatobiliary disorders Liver Injury	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Pulmonary Embolism	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Biliary Tract Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bronchial Neoplasm	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Eye disorders Retinal Vein Occlusion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Chest Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • Number of events 2 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Hepatobiliary disorders Cholecystitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Disease Progression	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.5% 4/73 • Number of events 4 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Clostridium Difficile Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Clostridium Difficile Colitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Gallbladder Perforation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Psychiatric disorders Confusional State	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Deep Vein Thrombosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Pulmonary Haemorrhage	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Colitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Dehydration	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	40.0% 2/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • Number of events 3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Infusion Related Reaction	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Diarrhoea	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Encephalopathy	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • Number of events 2 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Enterococcal Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Epilepsy	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Oesophageal Ulcer Haemorrhage	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Fatigue	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Fever	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Colonic Perforation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Gastrointestinal Perforation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Gastrointestinal Haemorrhage	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • Number of events 2 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Hemiparesis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Hypertension	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Haemorrhage Intracranial	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Lower Gastrointestinal Haemorrhage	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Pneumonia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Meningitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Migraine	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Multi-organ Failure	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Myocardial Infarction	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • Number of events 2 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Back Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • Number of events 2 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Pancreatitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Paraparesis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Femur Fracture	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Reproductive system and breast disorders Pelvic Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Pleural Effusion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Pneumothroax	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Posterior Reversible Encephalopothy Syndrome	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Respiratory Failure	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Seizure	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Sepsis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • Number of events 2 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Headache	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Spinal Fracture	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Vomiting	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Muscular Weakness	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • Number of events 1 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Pyrexia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.

Other adverse events

Measure	P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=3 participants at risk Phase 1b Dose Level 1: 8 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=15 participants at risk Phase 1b Dose Level 2: 10 mg/kg TRC105 weekly in combination with 5 mg Axitinib twice daily	P1b: 10 mg/kg Wkly/15 mg/kg q2wks TRC105 + 5 mg Axitinib BID n=5 participants at risk Phase 1b Dose Level 3: 10 mg/kg TRC105 weekly during cycle 1 then 15 mg/kg TRC105 every two weeks beginning in cycle 2 in combination with 5 mg Axitinib twice daily	P2 Arm A: 5 mg Axitinib BID n=74 participants at risk Phase 2 Arm A: 5 mg Axitinib twice daily	P2 Arm B: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID n=73 participants at risk Phase 2 Arm B: 10 mg/kg TRC105 weekly + 5 mg Axitinib twice daily
Gastrointestinal disorders Abdominal Discomfort	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Abdominal Distension	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 3/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Abdominal Hernia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Abdominal Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	33.3% 5/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.7% 10/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Abdominal Pain Lower	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Abdominal Pain Upper	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	15.1% 11/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Abdominal Tenderness	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Psychiatric disorders Abnormal Dreams	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Acne	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Actinic Keratosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Activated Partial Thromboplastin Time Prolonged	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Acute Coronary Syndrome	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Acute Kidney Injury	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Endocrine disorders Adrenal Insufficiency	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Psychiatric disorders Agitation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Alanine Aminotransferase Increased	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.5% 4/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Amnesia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Blood and lymphatic system disorders Anaemia	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	26.7% 4/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	16.2% 12/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	21.9% 16/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Anal Abscess	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Angina Pectoris	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Anorectal Discomfort	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Psychiatric disorders Anxiety	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Aortic Aneurysm	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Arrhythmia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Arteriosclerosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.5% 10/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	11.0% 8/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Ascites	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Aspartate Aminotransferase Increased	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 3/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	9.5% 7/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Asthenia	100.0% 3/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	12.2% 9/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.2% 6/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Back Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 3/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	23.0% 17/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	9.6% 7/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Balance Disorder	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal Cell Carcinoma	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Benign Neoplasm	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Ear and labyrinth disorders Cerumen Impaction	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Hepatobiliary disorders Bile Duct Stenosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Bladder Spasm	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Blister	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Blood Alkaline Phosphatase Increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	9.6% 7/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Blood Amylase Increased	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	9.5% 7/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Blood Bilirubin Increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Blood Creatinine Increased	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	12.2% 9/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Blood Pressure Increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Blood Thyroid Stimulating Hormone Decreased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Blood Thyroid Stimulating Hormone Increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Blood Urea Increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Bone Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Brachycardia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast Cancer	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Reproductive system and breast disorders Breast Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Bronchitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Bundle Branch Block Right	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Burning Sensation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Cachexia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Candidiasis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Cardiac Disorder	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Cardiac Failure	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Cardiac Failure Acute	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Cardiac Murmur	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Eye disorders Cataract	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Catheter Site Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Catheter Site Swelling	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Cellulitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Cerebrovascular Accident	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Cheilitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Chest Discomfort	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Chest Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Chills	100.0% 3/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	9.5% 7/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	15.1% 11/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Choking Sensation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Hepatobiliary disorders Cholelithiasis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Cognitive Disorder	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Colitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Surgical and medical procedures Colostomy	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Psychiatric disorders Confusional State	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.5% 4/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Constipation	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	33.3% 5/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	40.0% 2/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	17.6% 13/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	28.8% 21/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Contusion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Convulsion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Coronary Artery Disease	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Coronary Artery Thrombosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Cough	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	33.3% 5/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.3% 15/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	19.2% 14/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Cystitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Dacryocanaliculitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Decreased Appetite	100.0% 3/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	33.3% 5/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	60.0% 3/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	35.1% 26/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	28.8% 21/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Decubitus Ulcer	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Deep Vein Thrombosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Dehydration	100.0% 3/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	9.5% 7/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	15.1% 11/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Psychiatric disorders Delirium	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Dental Caries	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Psychiatric disorders Depression	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Dermatitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Dermatitis Acneiform	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 3/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.5% 4/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Dermatitis Bullous	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Diarrhoea	100.0% 3/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	73.3% 11/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	80.0% 4/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	62.2% 46/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	57.5% 42/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Diarrhoea Infectious	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Diastolic Dysfunction	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Disturbance In Attention	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Diverticulum	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Dizziness	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 3/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	12.2% 9/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.7% 10/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Dizziness Postural	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Drug Intolerance	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Eye disorders Dry Eye	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Dry Mouth	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	9.5% 7/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	9.6% 7/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Dry Skin	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.5% 4/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Dry Throat	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Dysaesthesia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Dysgeusia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	12.2% 9/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.7% 10/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Dyskinesia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Dyskinesia Oesophageal	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Dyspepsia	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.5% 10/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.2% 6/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Dysphagia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Dysphonia	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	40.0% 6/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	60.0% 3/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	36.5% 27/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	26.0% 19/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Dyspnoea	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.5% 10/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	16.4% 12/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Dyspnoea Exertional	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Dysuria	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Ear and labyrinth disorders Ear Discomfort	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Ear and labyrinth disorders Ear Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Electrocardiogram QT Prolonged	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Embolism	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Encephalopathy	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Enteritis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Epidermal Growth Factor Receptor Increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Epistaxis	66.7% 2/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	86.7% 13/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	100.0% 5/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	64.4% 47/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Reproductive system and breast disorders Erectile Dysfunction	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.2% 6/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Eye disorders Eye Discharge	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Eye disorders Eye Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Facial Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Faecal Incontinence	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Faeces Discoloured	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Faeces Pale	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Fall	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.5% 4/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Fatigue	100.0% 3/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	60.0% 9/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	80.0% 4/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	54.1% 40/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	57.5% 42/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Feeling Cold	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Feeling Hot	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Flank Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Flatulence	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	9.6% 7/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Flushing	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	9.6% 7/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Folliculitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Food Intolerance	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Fungal Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Fungal Skin Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Furuncle	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Hepatobiliary disorders Gallbladder Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Gamma-Glutamyltransferase Increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Gastritis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Gastrointestinal Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Gastrooesophageal Reflux Disease	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Reproductive system and breast disorders Genital Discharge	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders General Physical Health Deterioration	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Gingival Bleeding	66.7% 2/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	46.7% 7/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	100.0% 5/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	34.2% 25/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Gingival Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Gingival Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.5% 4/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Glossitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Glossodynia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Glucose Tolerance Impaired	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Glucose Urine Present	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Glycosuria	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Gout	66.7% 2/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Groin Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Reproductive system and breast disorders Gynaecomastia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Haematemesis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Haematochezia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Haematoma	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Haematuria	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	11.0% 8/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Haemoglobin Increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Haemorrhage	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Haemorrhoidal Haemorrhage	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Haemorrhoids	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.5% 4/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Head Injury	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Headache	100.0% 3/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	66.7% 10/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	40.0% 2/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	16.2% 12/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	64.4% 47/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Ear and labyrinth disorders Hearing Impaired	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Hepatobiliary disorders Hepatitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Hiatus Hernia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Hiccups	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Hot Flush	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Hydronephrosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Hyperaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Hyperaesthesia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Endocrine disorders Hypercalcaemia of malignancy	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypercholesterolaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.1% 6/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Hyperhidrosis	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hyperkalaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Hyperkeratosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypernatraemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 3/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Immune system disorders Hypersensitivity	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Hypersomnia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Hypertension	66.7% 2/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	26.7% 4/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	80.0% 4/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	44.6% 33/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	35.6% 26/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Endocrine disorders Hyperthyroidism	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Ear and labyrinth disorders Hypoacusis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Hypoaesthesia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypoalbuminaemia	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypoglycaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypokalaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hyponatraemia	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	16.4% 12/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypophosphataemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.1% 6/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypoproteinaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Hypotension	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	9.6% 7/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Endocrine disorders Hypothyroidism	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	27.0% 20/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	23.3% 17/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Hypotonia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypovolaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Incision Site Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Incisional Hernia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Increased Upper Airway Secretion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Influenza	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Influenza Like Illness	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Infusion Related Reaction	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 3/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	26.0% 19/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Infusion Site Erythema	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Infusion Site Extravasation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Ingrowing Nail	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Inguinal Mass	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Injection Site Erythema	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Injection Site Haemorrhage	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Injection Site Mass	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Psychiatric disorders Insomnia	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 3/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.1% 6/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations International Normalised Ratio Increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Iron Binding Capacity Total Decreased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Joint Injury	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Joint Swelling	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Kidney Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Laceration	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Eye disorders Lacrimation increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Large Intestine Perforation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Left Ventricular Dysfunction	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Lethargy	66.7% 2/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Blood and lymphatic system disorders Leukocytosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Blood and lymphatic system disorders Leukopenia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Limb Injury	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Lipase Increased	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Livedo Reticularis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Hepatobiliary disorders Liver Disorder	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Liver Function Test Abnormal	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Liver Function Test Increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Local Swelling	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Lower Limb Fracture	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Lung Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Lymph Gland Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Lymphocyte Count Decreased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Malaise	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Medical Device Site Bruise	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Melaena	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Memory Impairment	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Mental Impairment	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Psychiatric disorders Mental Status Changes	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Mesenteric Vein Thrombosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Metabolic Encephalopathy	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Blood and lymphatic system disorders Microcytic Anaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Micturition Urgency	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Migraine	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Mitral Valve Incompetence	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Mouth Haemorrhage	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Mouth Ulceration	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Mucosal Inflammation	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	46.7% 7/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.1% 6/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.7% 10/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Muscle Spasms	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Muscle Strain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Muscular Weakness	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.5% 4/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Musculoskeletal Chest Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Musculoskeletal Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.1% 6/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	9.6% 7/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Mycobacterium Tuberculosis Complex Test Positive	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Nail Discolouration	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Nail Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Nasal Congestion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.2% 6/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Nasal Dryness	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Nasal Septum Disorder	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Nasal Septum Perforation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Nasal Septum Ulceration	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Nasal Ulcer	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Nasopharyngitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Nausea	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	60.0% 9/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	80.0% 4/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	36.5% 27/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	52.1% 38/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Neck Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Nephrolithiasis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Neuropathy Peripheral	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Blood and lymphatic system disorders Neutropenia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Night Sweats	66.7% 2/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 3/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Reproductive system and breast disorders Nipple Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Non-Cardiac Chest Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Oedema	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Oedema Peripheral	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Oesophageal Ulcer	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Oesophagitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Oral Candidiasis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Oral Discomfort	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Oral Disorder	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Oral Dysaesthesia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Oral Herpes	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.5% 4/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Oral Mucosal Erythema	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Oral Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	11.0% 8/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Oropharyngeal Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.1% 6/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	17.8% 13/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Orthostatic Hypotension	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Osteoporosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Otitis Externa	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Otitis Media	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Pain In Extremity	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	33.3% 5/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.1% 6/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	19.2% 14/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Pain In Jaw	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Palmar-plantar Erythrodysaesthesia Syndrome	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	33.3% 5/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	40.0% 2/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.3% 15/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	24.7% 18/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Palmoplantar Keratoderma	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Paraesthesia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Paraesthesia Oral	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Paresis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Paronychia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Pathological Fracture	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Reproductive system and breast disorders Pelvic Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Peptic Ulcer	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Pericardial Effusion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Periodontal Disease	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Eye disorders Periorbital Oedema	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Peripheral Sensory Neuropathy	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Pharyngitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Eye disorders Photophobia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Photosensitivity Reaction	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Plantar Fasciitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Platelet Count Decreased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Pleural Effusion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Pneumonia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Pollakiuria	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Blood and lymphatic system disorders Polycythaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Post Procedural Discomfort	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Presyncope	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Proctalgia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Productive Cough	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.5% 4/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Reproductive system and breast disorders Prostatic Obstruction	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Proteinuria	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.3% 2/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.3% 15/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Pulmonary Embolism	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Purpura	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Pyrexia	66.7% 2/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	26.7% 4/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	13.7% 10/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Rash	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 3/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.1% 6/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	16.4% 12/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Rash Erythematous	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Rash Macular	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Rash Maculo-papular	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.2% 6/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Rash Pruritic	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Rectal Haemorrhage	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Red Blood Cells Urine	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Renal Failure	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Respiratory Tract Congestion	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Retching	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Eye disorders Retinal Vein Occlusion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Rhinitis Allergic	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Rib Fracture	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Road Traffic Accident	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Rosacea	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Salivary Hypersecretion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Scab	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Sciatica	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Reproductive system and breast disorders Scrotal Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Immune system disorders Seasonal Allergy	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Sepsis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Sinus Bradycardia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Sinus Congestion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Sinus Headache	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Sinus Tachycardia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Sinusitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.1% 6/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Skin Abrasion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Skin Discolouration	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Skin Erosion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Skin Exfoliation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Skin Hyperpigmentation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Skin Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Skin Lesion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin Papilloma	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Skin Ulcer	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Sleep Apnoea Syndrome	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Spinal Cord Compression	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Spondylolisthesis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Staphylococcal Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Sternal Fracture	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Stomatitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	60.0% 3/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	10.8% 8/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	24.7% 18/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Subcutaneous Nodule	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Supraventricular Extrasystoles	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Swelling Face	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Swollen Tongue	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Syncope	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Tachycardia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Tachypnoea	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Telangiectasia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Temperature Intolerance	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Tendonitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Thermal Burn	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Thirst	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Blood and lymphatic system disorders Thrombocytosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Vascular disorders Thrombophlebitis Superficial	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Endocrine disorders Thyroid Disorder	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Tinea Cruris	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Tinea Pedis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Tinea Versicolour	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Ear and labyrinth disorders Tinnitus	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Tooth Abscess	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Surgical and medical procedures Tooth Extraction	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Tooth Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Toothache	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Transaminases Increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Tremor	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Tricuspid Valve Incompetence	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Ear and labyrinth disorders Tympanic Membrane Perforation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Type 2 Diabetes Mellitus	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Upper Respiratory Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	10.8% 8/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	8.2% 6/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Upper Respiratory Tract Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Upper Respiratory Tract Inflammation	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Upper-airway Cough Syndrome	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Urethral Meatus Stenosis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Urinary Incontinence	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Urinary Retention	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Urinary Tract Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	60.0% 3/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.8% 5/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Urinary Tract Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Vaginal Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Reproductive system and breast disorders Vaginal Lesion	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Ventricular Extrasystoles	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	4.1% 3/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Ear and labyrinth disorders Vertigo	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Viral Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Eye disorders Vision Blurred	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	5.4% 4/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Eye disorders Visual Impairment	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Vitamin D Decreased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Vomiting	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	33.3% 5/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	80.0% 4/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	18.9% 14/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	41.1% 30/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Vulvovaginal Mycotic Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Reproductive system and breast disorders Vulvovaginal Pain	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Wandering Pacemaker	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Weight Decreased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 3/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	40.0% 2/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	23.0% 17/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	37.0% 27/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations Weight Increased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Respiratory, thoracic and mediastinal disorders Wheezing	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations White Blood Cell Count Decreased	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Investigations White Blood Cells Urine	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Wound	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Wound Complication	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Injury, poisoning and procedural complications Wound Dehiscence	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	2.7% 2/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Wound Infection	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	1.4% 1/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
General disorders Gait Disturbance	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Eye disorders Ocular Hyperaemia	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Somnolence	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Speech Disorder	33.3% 1/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Duodenditis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Blood and lymphatic system disorders Haemolytic anaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hyperphosphataemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Metabolism and nutrition disorders Hypertriglyceridaemia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Impaired Gastric Emptying	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Renal and urinary disorders Incontinence	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Musculoskeletal and connective tissue disorders Musculoskeletal Stiffness	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Nasal Vestibulitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Cardiac disorders Palpitations	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Gastrointestinal disorders Periodontitis	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Skin and subcutaneous tissue disorders Petechiae	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Infections and infestations Pneumonial Staphylococcal	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Surgical and medical procedures Preventative Surgery	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	6.7% 1/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Nervous system disorders Ageusia	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	40.0% 2/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.
Ear and labyrinth disorders Ear Haemorrhage	0.00% 0/3 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/15 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	20.0% 1/5 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/74 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.	0.00% 0/73 • 2 years, 6 months Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. Only patients who received at least a portion of a dose of TRC105 and/or Axitinib have been included in the analysis population.

Additional Information

Charles Theuer

TRACON Pharmaceuticals Inc.

Phone: (858) 550-0780

Email: ctheuer@traconpharma.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place